A functional cell model using basophil activation test to study molecular mechanisms and biomarkers of response to omalizumab treatment in patients with asthma.

Front Immunol · 2026 · PMC12982396 · PMID 41836414

Europe PMC DOI

hedged sentence

0.0530

closest p · 1.1× alpha

0.0530

boldest claim

The sentences

showed a trendp=0.053so close (0.05 < p ≤ 0.1)

In this small group, the mean baseline RSAD2 expression in the basophils showed a trend toward higher expression compared to the poor/non-responder group (p=0.053, Supplementary Figure S5A ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.